Anbio Biotechnology (NNNN)

Anbio Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5.35	11.76	9.69	7.1	4.18
Short-Term Investments	8.08	-	-	1.57	-
Cash & Short-Term Investments	13.43	11.76	9.69	8.67	4.18
Cash Growth	30.25%	21.40%	11.75%	107.33%	-
Receivables	3.72	1.06	1.88	-	0.72
Inventory	-	-	-	0.35	-
Prepaid Expenses	10.54	5.71	4.17	4.92	0.02
Other Current Assets	-	0	0	0	0
Total Current Assets	27.68	18.53	15.75	13.94	4.92
Property, Plant & Equipment	-	-	-	0.01	-
Long-Term Deferred Charges	-	0.39	0.04	-	-
Other Long-Term Assets	-	-	0.02	0	-
Total Assets	27.68	18.92	15.81	13.96	4.92
Accounts Payable	0.06	1.63	0.83	1.41	1.89
Accrued Expenses	-	-	0.13	-	-
Other Current Liabilities	0.07	0.1	0.03	0	0.49
Total Current Liabilities	0.13	1.73	0.99	1.41	2.38
Total Liabilities	0.13	1.73	0.99	1.41	2.38
Common Stock	0.01	0.01	0.01	-	-
Additional Paid-In Capital	6.56	0	0	-	-
Retained Earnings	20.97	17.17	14.8	12.55	2.54
Shareholders' Equity	27.55	17.19	14.82	12.55	2.54
Total Liabilities & Equity	27.68	18.92	15.81	13.96	4.92
Net Cash (Debt)	13.43	11.76	9.69	8.67	4.18
Net Cash Growth	30.25%	21.40%	11.75%	107.33%	-
Net Cash Per Share	0.31	0.28	0.45	-	-
Filing Date Shares Outstanding	43.89	43.89	42.29	-	-
Total Common Shares Outstanding	43.89	42.29	42.29	-	-
Working Capital	27.55	16.8	14.76	12.53	2.54
Book Value Per Share	0.63	0.41	0.35	-	-
Tangible Book Value	27.55	17.19	14.82	12.55	2.54
Tangible Book Value Per Share	0.63	0.41	0.35	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q